After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?
Summary
(MedPage Today) -- CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products. "Across CAR T-cell...
Description from Medpagetoday.
Who is covering this
-
After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?
(MedPage Today) -- CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products. "Across CAR T-cell...
-
Zamto-Cel Improves EFS in Large B-Cell Lymphoma
A phase 2 trial compares dual-targeted CAR T-cell therapy with R-GemOx as second-line treatment for patients with relapsed or refractory large B-cell lymphoma who are ineligible for transplantation.
Related stories
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
29 sourcesvia BBC NewsTruth score 9111
Actor Ajay Devgn moves High Court against FDA notice over Vimal Elaichi ads
7 sourcesvia The HinduTruth score 731
Blood pressure medication recalled nationwide
4 sourcesvia USA TODAYTruth score 671
Trump administration says biggest changes coming to infant formula in nearly 30 years
2 sourcesvia ABC News (US)Truth score 533
FDA issues alert about Northfield-based Medline beds tied to fire-related deaths and injuries
3 sourcesvia Chicago Sun-TimesTruth score 59
Patanjali ghee among Rs 9 crore food stock seized in Maharashtra FDA crackdown
3 sourcesvia India TodayTruth score 54
Comments
Comments need JavaScript.